scispace - formally typeset
Search or ask a question
Institution

Université libre de Bruxelles

EducationBrussels, Belgium
About: Université libre de Bruxelles is a education organization based out in Brussels, Belgium. It is known for research contribution in the topics: Population & Breast cancer. The organization has 24974 authors who have published 56969 publications receiving 2084303 citations. The organization is also known as: ULB.


Papers
More filters
Journal ArticleDOI
Shona Hendry1, Roberto Salgado2, Thomas Gevaert3, Prudence A. Russell1, Prudence A. Russell4, Thomas John5, Thomas John1, Bibhusal Thapa1, Michael Christie6, Koen Van de Vijver7, Monica V. Estrada8, Paula I. Gonzalez-Ericsson9, Melinda E. Sanders, Benjamin sss Solomon10, Cinzia Solinas, Gert Van den Eynden, Yves Allory11, Yves Allory12, Matthias Preusser, Johannes A. Hainfellner13, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria14, Fraser Symmans15, Paolo Nuciforo, Laura Comerma, E. A. Thompson16, Sunil R. Lakhani17, Sunil R. Lakhani18, Seong-Rim Kim, Stuart J. Schnitt19, Cecile Colpaert, Christos Sotiriou2, Stefan J. Scherer20, Michail Ignatiadis2, Sunil Badve21, Robert H. Pierce22, Giuseppe Viale23, Nicolas Sirtaine2, Frédérique Penault-Llorca24, Tomohagu Sugie25, Susan Fineberg26, Soonmyung Paik27, Ashok Srinivasan, Andrea L. Richardson19, Yihong Wang28, Yihong Wang29, Ewa Chmielik30, Jane E. Brock19, Douglas B. Johnson9, Justin M. Balko9, Stephan Wienert31, Veerle Bossuyt32, Stefan Michiels, Nils Ternès, Nicole Burchardi, Stephen J Luen10, Stephen J Luen1, Peter Savas1, Peter Savas10, Frederick Klauschen31, Peter H. Watson33, Brad H. Nelson34, Carmen Criscitiello, Sandra A O'Toole35, Denis Larsimont2, Roland de Wind2, Giuseppe Curigliano, Fabrice Andre36, Magali Lacroix-Triki36, Mark van de Vijver7, Federico Rojo37, Giuseppe Floris3, Shahinaz Bedri14, Joseph A. Sparano26, David L. Rimm32, Torsten O. Nielsen33, Zuzana Kos38, Stephen M. Hewitt39, Baljit Singh40, Gelareh Farshid41, Sibylle Loibl, Kimberly H. Allison42, Nadine Tung19, Sylvia Adams40, Karen Willard-Gallo, Hugo M. Horlings, Leena Gandhi19, Leena Gandhi40, Andre L. Moreira40, Fred R. Hirsch43, Maria Vittoria Dieci44, Maria Urbanowicz45, Iva Brcic46, Konstanty Korski47, Fabien Gaire47, Hartmut Koeppen48, Amy C. Y. Lo48, Amy C. Y. Lo42, Jennifer M. Giltnane48, Marlon Rebelatto49, Keith Steele49, Jiping Zha49, Kenneth Emancipator50, Jonathan Juco50, Carsten Denkert31, Jorge S. Reis-Filho51, Sherene Loi10, Stephen B. Fox1 
TL;DR: In this paper, a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, was proposed.
Abstract: Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.

415 citations

Journal ArticleDOI
01 Jan 1997-BioDrugs
TL;DR: The multiple facets of r IL-10 in experimental immunopathology indicate that the success of clinical trials with rIL-10 will depend both on the appropriate selection of the patient populations to be treated and on the early detection of possible adverse effects.
Abstract: Interleukin-10 (IL-10) is a potent anti-inflammatory and immunosuppressive cytokine secreted by several cell types. Most anti-inflammatory effects of IL-10 are caused by its ability to deactivate macrophages and monocytes, whereas its immunosuppressive properties are due to functional inhibition of both antigen-presenting cells and T cells. On the other hand, IL-10 also exerts immunostimulatory effects, especially on B cells, CD8+ cytotoxic T cells and natural killer cells. In vivo administration of recombinant IL-10 (rIL-10) efficiently prevents experimental septic shock induced by endotoxin, staphylococcal superantigen or cecal ligation and puncture, as well as experimental autoimmune diseases mediated by T helper type 1 (T(H)1) cells and other inflammatory disorders. rIL-10 exerts paradoxical effects in cancer models, where it promotes tumour rejection, probably due to its stimulatory properties on cytotoxic cells. On the other hand, rIL-10 increases the severity of experimental infections caused by fungi or bacteria, and enhances systemic autoimmune features in mice with spontaneous lupus syndrome. Although the therapeutic potential of rIL-10 in human diseases seems promising, the multiple facets of rIL-10 in experimental immunopathology indicate that the success of clinical trials with rIL-10 will depend both on the appropriate selection of the patient populations to be treated and on the early detection of possible adverse effects.

415 citations

Journal ArticleDOI
TL;DR: Because no etiologic therapy is available for Duchenne muscular dystrophy, a better understanding of the primary and downstream mechanisms could prove useful for producing new adjuvant treatments.

413 citations

Journal ArticleDOI
TL;DR: A formal "small tension" expansion of D=11 supergravity near a spacelike singularity is shown to be equivalent, at least up to 30th order in height, to a null geodesic motion in the infinite-dimensional coset space E(10)/K(E 10), where K(E10) is the maximal compact subgroup of the hyperbolic Kac-Moody group E10(R).
Abstract: A formal ``small tension'' expansion of $D=11$ supergravity near a spacelike singularity is shown to be equivalent, at least up to 30th order in height, to a null geodesic motion in the infinite-dimensional coset space ${E}_{10}/K({E}_{10})$, where $K({E}_{10})$ is the maximal compact subgroup of the hyperbolic Kac-Moody group ${E}_{10}(\mathbb{R})$. For the proof we make use of a novel decomposition of ${E}_{10}$ into irreducible representations of its $\mathrm{S}\mathrm{L}(10,\mathbb{R})$ subgroup. We explicitly show how to identify the first four rungs of the ${E}_{10}$ coset fields with the values of geometric quantities constructed from $D=11$ supergravity fields and their spatial gradients taken at some comoving spatial point.

413 citations

Journal ArticleDOI
TL;DR: An observational study conducted in ICUs around the world to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid and to compare the proportion of patients receiving further fluid administration based on the response to the FC.
Abstract: Background Fluid challenges (FCs) are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units. There are clear benefits and harms from fluid therapy. Limited data on the indication, type, amount and rate of an FC in critically ill patients exist in the literature. The primary aim was to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid; the secondary aim was to evaluate variables used to trigger an FC and to compare the proportion of patients receiving further fluid administration based on the response to the FC.

413 citations


Authors

Showing all 25206 results

NameH-indexPapersCitations
Karl J. Friston2171267217169
Yi Chen2174342293080
David Miller2032573204840
Jing Wang1844046202769
H. S. Chen1792401178529
Jie Zhang1784857221720
Jasvinder A. Singh1762382223370
D. M. Strom1763167194314
J. N. Butler1722525175561
Andrea Bocci1722402176461
Bradley Cox1692150156200
Marc Weber1672716153502
Hongfang Liu1662356156290
Guenakh Mitselmakher1651951164435
Yang Yang1642704144071
Network Information
Related Institutions (5)
University of Paris
174.1K papers, 5M citations

96% related

Utrecht University
139.3K papers, 6.2M citations

93% related

University of Amsterdam
140.8K papers, 5.9M citations

93% related

Centre national de la recherche scientifique
382.4K papers, 13.6M citations

93% related

Sapienza University of Rome
155.4K papers, 4.3M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023119
2022411
20213,194
20203,051
20192,751
20182,609